In vivo toxicity of Id-peptides
| Group . | IL-1β, pg/mL . | GSH, mM . | LDH, IU/L . |
|---|---|---|---|
| Untreated | 59 ± 0.01 | 0.006 ± 0.001 | 80.0 ± 15.1 |
| pCNT-treated | 60 ± 0.02 | 0.006 ± 0.001 | 68.6 ± 23.8 |
| pA20-36–treated | 59 ± 0.01 | 0.006 ± 0.001 | 73.2 ± 19.2 |
| Group . | IL-1β, pg/mL . | GSH, mM . | LDH, IU/L . |
|---|---|---|---|
| Untreated | 59 ± 0.01 | 0.006 ± 0.001 | 80.0 ± 15.1 |
| pCNT-treated | 60 ± 0.02 | 0.006 ± 0.001 | 68.6 ± 23.8 |
| pA20-36–treated | 59 ± 0.01 | 0.006 ± 0.001 | 73.2 ± 19.2 |
Three groups of tumor-free BALB/c mice (5 mice/group) were left untreated, or intraperitoneally inoculated daily with either pA20-36– or pCNT-peptide (20 mg ≃ kg−1 ≃ d−1) for 2 weeks, after which blood samples were collected and analyzed for IL-1β, glutathione (GSH), and lactate dehydrogenase (LDH). Values represent the mean ± SEM of 3 different experiments.